Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Skov3 cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oophoroma multidrug resistance cell strain established by etoposide induction
The invention relates to a multidrug resistant cell strain for oophoroma, which is characterized in that a human oophoroma SKOV3 cell strain is selected as a parental cell; the action concentration of chemotherapeutics of etoposide (VP16) is gradually increased from 0.1 mu g / ml to 3 mu g / ml; and drug resistant SKOV3 / VP16 cell strain is established. The SKOV3 / VP16 cell can stably grow, transfer and reanimate in 3 mu g / ml VP16, makes the VP16 generate drug resistant index (RI) of 21.548, and performs intersect drug on MTX, DOX, DDP, VCR, 5-Fu and MMC except the VP16. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
Platinum complex for inhibiting cell SKOV3 and synthesis method of platinum complex
ActiveCN107501331AHigh antitumor activityHigh efficiency and low toxicityPlatinum organic compoundsAntineoplastic agentsPlatinum complexSynthesis methods
The invention discloses a platinum complex for inhibiting cell SKOV3 and a synthesis method of the platinum complex, belongs to the technical field of medicines, and aims to provide a cell SKOV3 inhibiting platinum complex synthesized from rutaecarpine as structural basis and DMSO as an auxiliary ligand. The invention further provides a synthesis method of the platinum complex. The structural formula of the platinum complex is as shown in the description. The platinum complex can be used for preparing anti-tumor drugs.
Owner:YULIN NORMAL UNIVERSITY
Application of carbon quantum dots/cuprous oxide (CQDs/Cu2O) compound to preparation of cancer treating medicines
PendingCN107569515APrevent proliferationInhibit expressionCarbon active ingredientsAntineoplastic agentsMedicineNormal cell
The invention discloses application of a carbon quantum dots / cuprous oxide (CQDs / Cu2O) compound to preparation of cancer treating medicines. Through in-vitro cell experiments, the anticancer activityof the CQDs / Cu2O is explored; after the CQDs / Cu2O acts on five types of cancer cells, namely HeLa, A549, HT-29, SKOV3 and BABL-3T3, for 72h, the IC50 value is 1.25-18.9[mu]g.mL<-1>, the cancer cell proliferation inhibiting effect is higher than the normal cell proliferation inhibiting effect, and the toxicity and side effects on normal cells are relatively low; when the concentration is 12.5[mu]g.mL<-1>, the cancer cell inhibiting rate is higher than 50%; the CQDs / Cu2O has the strongest SKOV3 cell inhibiting effect, and the IC50 value is 12.5[mu]g.mL<-1>; the CQDs / Cu2O is the most sensitive toSKOV3 cells.
Owner:YUNNAN UNIV
Application of Cephaloziellin B in preparation of medicine for treating ovarian cancer
InactiveCN105055395AAntineoplastic agentsHeterocyclic compound active ingredientsGynecologyInhibitory effect
The invention discloses application of Cephaloziellin B in the preparation of a medicine for treating an ovarian cancer, and belongs to the field of medicines. A research shows that the Cephaloziellin B has an inhibition effect on the proliferation of SKOV3 cells of the ovarian cancer, the inhibition rate is concentration-dependent and time-dependent, and the Cephaloziellin B can be further researched and developed to prepare the medicine for treating the ovarian cancer.
Owner:赵东顺
Herba balanophorae involucratae extract and application thereof to preparation of anticancer medicine
Owner:CHINA THREE GORGES UNIV
Application of Chenopodolin in preparation of medicines for treating ovarian cancer
The invention discloses an application of Chenopodolin in preparation of medicines for treating an ovarian cancer, and belongs to the field of medicines. An in vitro test proves that the Chenopodolin is capable of inhibiting proliferation activity of an ovarian cancer SKOV3 cell; an MTT result shows that distribution of a cell cycle is affected by the Chenopodolin; tumor cells are retarded at a G0 / G1 stage; meanwhile, the Chenopodolin can be combined with a tyrosine kinase phosphorylation ATP binding site of an EGFR / HER2 acceptor to inhibit phosphorylation of tyrosine kinase, so that cell apoptosis is induced by down-regulating expression of HER2 and P-HER2 protein; and the Chenopodolin can be further researched and developed into the medicines for treating the ovarian cancer.
Owner:吴正锋
Application of long-chain non-coding RNA LINC00205 in preparation of reagent for diagnosing ovarian cancer or medicament for treating ovarian cancer
ActiveCN110029166AOrganic active ingredientsMicrobiological testing/measurementNon-coding RNATranscriptome Sequencing
MEHP treatment significantly increases the migration and invasion ability of tumor cells, and the results show that MEHP can induce epithelial-mesenchymal transition of ovarian cancer cells. SKOV3 cells treated by the MEHP with a concentration of 500nM are subjected to transcription group sequencing by a high-throughput sequencing method, the sequencing result is analyzed, and 39 confirmed long-chain non-coding RNAs are screened out; and in the differentially-expressed 39 lnc RNAs, the results show that linc00205 plays an important role in the ovarian cancer cell migration, invasion ability improvement and epithelial-mesenchymal transition induced by the MEHP.
Owner:ZHEJIANG UNIV
Application of ledene in cervical cancer treatment aspect
InactiveCN109432069AStrong growth inhibitory effectHydroxy compound active ingredientsAntineoplastic agentsChemical structureIsorupestonic acid
The invention discloses an application of ledene in a cervical cancer treatment aspect. It is discovered that gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have the excellent anti-proliferative effect to a human ovarian cancer SKOV3 cell and a human cervical cancer Hela cell; and although the ledene is a dehydration product of palustrol from a chemical structure, and the chemical structure is more similar, a difference of proliferation inhibition activity to the human ovarian cancer SKOV3 cell and the human cervical cancer Hela cell is larger, wherein the ledene is apparent for the anti-proliferative effect to the human cervical cancer Hela cell, and not apparent for the anti-proliferative effect to the human ovarian cancer SKOV3 cell, but the palustrolis apparent for the anti-proliferative effect to the human ovarian cancer SKOV3 cell, and not apparent for the anti-proliferative effect to the human cervical cancer Hela cell. All of the ledene, thepalustrol, the gweicurculactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene can be used for treating gynecological oncology.
Owner:淮安培元基因科技有限公司
Use of ledol in treating ovarian cancer
InactiveCN109223733AStrong growth inhibitory effectHydroxy compound active ingredientsAnhydride/acid/halide active ingredientsMANNITOL/SORBITOLCervix
The invention discloses use of ledol in treating ovarian cancer. The present inventors have found that cinnabarinol, isoamyl sulphonic acid, 7-seriesene ketone, and ketone orange have excellent proliferation inhibition effects on human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; Although the chemical structure is a dehydration product of tallow tea alcohol, the chemical structure is similar, but the proliferation inhibitory activity of human ovarian cancer SKOV3 cells and human cervical cancer Hela cells is quite different, among which: trumpet tea is on the cervical cervix. The proliferation inhibition effect of cancer Hela cells was obvious, and the inhibition of proliferation of human ovarian cancer SKOV3 cells was not obvious, while tallow tea alcohol inhibited theproliferation of human ovarian cancer SKOV3 cells, and inhibited the proliferation of human cervical cancer Hela cells. Terpene catechin, trumpet tea alcohol, cinnabarinol, isoamyl sulphonic acid, 7-mannitol ketone and 4 citron are all used for the treatment of gynecological tumors.
Owner:淮安培元基因科技有限公司
Preparation method of miR-126 transfected ovarian cancer cell line
The invention discloses a preparation method of an miR-126 transfected ovarian cancer cell line. The preparation method comprises the following steps: 1, culture of parental cells: conducting subculturing on a human ovarian mucinous cystadenocarcinoma cell line SKOV3; 2, transfection preparation of miR-126: using a lentiviral technology, inoculating the SKOV3 cells in logarithmic phase obtained in the step 1 into a 6 cm petri dish, adding 2 ml of a whole culture medium, and washing medium cells again with 2 ml of a serum-free medium when cells grow to 80%-90% fusion 24 hours later, and getting ready for transfection; and 3, arrangement of an miR-126 transfection overexpression group. The miR-126 transfection overexpression group has the following purposes: observation on biological behavior changes of ovarian cancer cells after miR-126 transfection; and research on effect of miR-126 in occurrence and development of ovarian cancer and searching for new targets for clinical treatment of ovarian cancer.
Owner:ZHEJIANG UNIV
Cyano vinylene derivative fluorescent dye as well as preparation method and application thereof
ActiveCN111057009AEasy to detectHigh selectivityStyryl dyesMethine/polymethine dyesChemical compoundCombinatorial chemistry
The invention relates to a cyanovinylene derivative fluorescent dye as well as a preparation method and application thereof, and discloses a compound represented by a structural general formula (I), and the compound R1 is independently selected from H, NH2, OH, CN, CH3, COOH, SO3H, F, Cl, Br or NO2; R2 is a group described in the specification. The compound probe molecule provided by the inventioncan realize quantitative detection of beta-Gal in a buffer solution test system, is not interfered by other proteases, biological mercaptan, active oxygen and common cations, and is successfully applied to in-situ detection of beta-Gal in biological cells of SKOV3 cells.
Owner:NORTHWEST UNIV(CN)
Daylily antitumor active protein as well as preparation method and application thereof
ActiveCN112552387AHigh activityInhibition of survivalPeptide/protein ingredientsPeptide preparation methodsCancer cellActive protein
The invention relates to the field of preparation and application of vegetable protein, and particularly belongs to daylily antitumor active protein as well as a preparation method and application thereof. The specific preparation method comprises the following steps: cutting daylily into pieces, adding a protein extracting solution, performing stirring overnight at 4 DEG C, adding precooled acetone to precipitate protein at low temperature, and carrying out dissolution with the protein extracting solution after centrifugation to obtain crude daylily protein; and separating and purifying antitumor active components in the daylily crude protein by adopting ammonium sulfate fractional precipitation and cation exchange chromatography to obtain the daylily antitumor active protein. The proteincan obviously inhibit the survival of liver cancer HepG2 and Bel-7402 cells, colorectal cancer DLD1 cells, breast cancer MCF-7 cells, cervical cancer HeLa cells and ovarian adenocarcinoma SKOV3 cells, and can be applied to the preparation of antitumor drugs.
Owner:SHANXI UNIV
Application of timosaponin I in preparation of medicine for resisting human ovarian cancer
ActiveCN113509479APrevent proliferationInhibit migrationOrganic active ingredientsAntineoplastic agentsChemical structurePharmaceutical drug
The invention provides application of timosaponin I in preparation of anti-human ovarian cancer drugs, and belongs to the technical field of new medical application of the timosaponin I. The molecular formula of the timosaponin I is C39H66O14, and the chemical structural formula of the timosaponin I is shown in the specification. The timosaponin I can effectively inhibit expression of mRNA of SHH signal channel related target genes and protein GLI1 and SUFU in human ovarian cancer cells SKOV3; the timosaponin I can effectively inhibit proliferation, epithelial-mesenchymal transition (EMT), migration and invasion of SKOV3 cells, and it is indicated that the timosaponin I is expected to be developed into an effective component of the medicine for resisting the human ovarian cancer. In addition, the medicine can be prepared into different preparation forms according to the requirements of patients, is convenient for the patients to take, and has better development and application prospects.
Owner:NANJING MEDICAL UNIV
Medical application of isorupestonic acid for treating gynecological tumors
InactiveCN109364044AStrong growth inhibitory effectHydroxy compound active ingredientsAnhydride/acid/halide active ingredientsChemical structureGynecologic Tumor
The invention discloses a medical application of isorupestonic acid for treating gynecological tumors. The medical application discovers that Gui curcumalactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have excellent proliferation-inhibiting effect for human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; ledene is a dewatered product of ledol from chemical structure, the chemical structures are more similar, but the difference of the human ovarian cancer SKOV3 cells and the human cervical cancer Hela cells is larger in proliferation-inhibiting activity, wherein the ledene has obvious proliferation-inhibiting effect for the human cervical cancer Hela cells, and has no obvious proliferation-inhibiting effect for the human ovarian cancer SKOV3 cells,but the ledol has obvious proliferation-inhibiting effect for the human ovarian cancer SKOV3 cells, and has no obvious proliferation-inhibiting effect for the human cervical cancer Hela cells. All the ledene, the ledol, the Gui curcumalactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene can be used for treating the gynecological tumors.
Owner:淮安培元基因科技有限公司
Compound with antitumor effect and its preparation method and application
ActiveCN109232662BEnhanced inhibitory effectTreatment targetingRhodium organic compoundsAntineoplastic agentsPentamethylcyclopentadieneProstate cancer cell
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Application of long-chain non-coding rna LINC00205 in the preparation of reagents for diagnosing ovarian cancer or drugs for treating ovarian cancer
ActiveCN110029166BOrganic active ingredientsMicrobiological testing/measurementParanasal Sinus CarcinomaPharmaceutical drug
MEHP treatment significantly increases the migration and invasion ability of tumor cells, and the results show that MEHP can induce epithelial-mesenchymal transition of ovarian cancer cells. SKOV3 cells treated by the MEHP with a concentration of 500nM are subjected to transcription group sequencing by a high-throughput sequencing method, the sequencing result is analyzed, and 39 confirmed long-chain non-coding RNAs are screened out; and in the differentially-expressed 39 lnc RNAs, the results show that linc00205 plays an important role in the ovarian cancer cell migration, invasion ability improvement and epithelial-mesenchymal transition induced by the MEHP.
Owner:ZHEJIANG UNIV
Ovarian cancer multi-drug resistant cell line induced by triptolide and its application
ActiveCN104805057BMicrobiological testing/measurementMicroorganism based processesGenetic divergenceCross-resistance
Owner:HARBIN MEDICAL UNIVERSITY
Medical application of 7-aromadendrene-6-ketone or 4-aromadendrene in field of gynaecology
InactiveCN109316471AStrong growth inhibitory effectHydroxy compound active ingredientsAntineoplastic agentsChemical structureKetone
The invention discloses medical application of 7-aromadendrene-6-ketone or 4-aromadendrene in the field of gynaecology. The invention discovers that gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have an excellent proliferation inhibition effect on human ovarian cancer SKOV3 cells and human cervical cancer Hela cells; despite that ledene is a dehydrated productof ledol in chemical structure, and has a relatively similar chemical structure, ledene shows great difference in the proliferation inhibition activity on the human ovarian cancer SKOV3 cells and human cervical cancer Hela cells, wherein the ledene realizes an obvious proliferation inhibition effect on the human cervical cancer Hela cells but an unapparent proliferation inhibition effect on the human ovarian cancer SKOV3 cells, while the ledol realizes an obvious proliferation inhibition effect on the human ovarian cancer SKOV3 cells but an unapparent proliferation inhibition effect on the human cervical cancer Hela cells. The ledene, the ledol, the gweicurculactone, the isorupestonic acid, the 7-aromadendrene-6-ketone and the 4-aromadendrene all can be used for treating gynecological tumors.
Owner:淮安培元基因科技有限公司
Oophoroma multidrug resistance cell strain established by etoposide induction
InactiveCN101503675BIncreased drug resistanceStable growthArtificial cell constructsTumor/cancer cellsCell strainWilms' tumor
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
Paclitaxel platinum co-loaded targeting long-circulating liposome and application thereof
ActiveCN112656764AEffective treatmentImprove the effect of targeted therapyOrganic active ingredientsInorganic active ingredientsCarboplatinCholesterol
The invention discloses a paclitaxel and platinum co-loaded targeting long-circulating liposome and application thereof. The liposome is formed by reacting paclitaxel, platinum drugs, a DSPE-G2000-ES targeting fragment, an mPEG2000-DSPE long-acting fragment, lecithin and cholesterol; wherein the platinum medicine is prepared from any one of cis-platinum, oxaliplatin and carboplatin. According to the paclitaxel platinum co-loaded targeting long-circulating liposome, a targeting fragment is used as a fragment for specifically recognizing an estrogen receptor, specifically recognizes and is combined with the estrogen receptor on the surface of an SKOV3 cell, so that the ingestion of the liposome is increased; the long-acting fragment reduces the capture interference of the liposome with albumin and reticuloendothelial systems in vivo, and prolongs the circulation time of the liposome in vivo; the IC50 value of the liposome to SKOV3 cells is 0.20-0.23 [mu]M, the tumor inhibition rate is 65-90%, and the liposome has a very good anti-ovarian cancer effect.
Owner:JILIN UNIV
Cyanovinylidene derivative fluorescent dye and its preparation method and application
ActiveCN111057009BEasy to detectHigh selectivityStyryl dyesMethine/polymethine dyesChemical compoundCombinatorial chemistry
Fluorescent dyes based on cyanovinylidene derivatives and their preparation methods and applications, the invention discloses a compound represented by the general structural formula (I), the compound R 1 independently selected from H, NH 2 , OH, CN, CH 3 , COOH, SO 3 H, F, Cl, Br or NO 2 ; 2 for. The compound probe molecule of the present invention can realize the quantitative detection of β-Gal in the buffer solution test system without interference from other proteases, biothiols, reactive oxygen species and common cations, and has been successfully applied to SKOV3 cells for the detection of β-Gal in biological cells In situ detection of Gal.
Owner:NORTHWEST UNIV
Anti-tumor pharmaceutical composition and application thereof
ActiveCN112316153AReduced survival rateWeak toxicityOrganic active ingredientsGenetic material ingredientsRenal Tubular Epithelial CellsOncology
The invention relates to the technical field of biological pharmacy, and particularly discloses an anti-tumor pharmaceutical composition and application thereof. The pharmaceutical composition comprises alendronate calcium and an exogenous gene. The pharmaceutical composition is high in safety, can reduce survival rate of human ovarian cancer cell SKOV3 cells, and reduce growth of tumor cells, buthas weak toxicity to human renal tubular epithelial cells HK2.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN
Benzylamino-substituted fatty acid derivative as well as preparation method and application thereof
PendingCN114702383AImprove anti-tumor activityHigh inhibition rateOrganic compound preparationPreparation from carboxylic acid esters/lactonesCancer cellNasopharyngeal carcinoma
The invention belongs to the technical field of medicines, and particularly relates to a benzylamino-substituted fatty acid derivative as well as a preparation method and application thereof. The benzylamino-substituted fatty acid derivative disclosed by the invention is (R, E) 5-(benzyloxy)-2-hexylhexadecane-2-olefine acid, and is obtained by synthesizing a raw material 3-hexyltetrahydro-4-hydroxy-6-undecyl-2H-pyran-2-ketone, and the raw material has the following structural formula shown in the description. Under the test concentration of 40 [mu] M, the inhibition rate of the prepared derivative on pancreatic cancer PANC-1, head and neck cancer TCA8113 and breast cancer MCF-7 cells is up to 80% or above, the inhibition rate on liver cancer HepG2, nasopharynx cancer CNE-2, kidney cancer A498 and bladder cancer T24 cells is 70-80%, the inhibition activity on ovarian cancer SKOV3 cells can reach 65.8%, and the derivative can be applied to preparation of antitumor drugs.
Owner:ZHONGSHAN WANHAN PHARM CO LTD
Wenwang Yibi Extract and Its Application in the Preparation of Anticancer Drugs
Owner:CHINA THREE GORGES UNIV
A platinum complex for inhibiting skov3 cells and its synthesis method
ActiveCN107501331BThe synthesis method is simpleGentle synthesis methodGroup 8/9/10/18 element organic compoundsAntineoplastic agentsEvodiaminePlatinum complex
Owner:YULIN NORMAL UNIVERSITY
Compound with chemotherapy and phototherapy anti-tumor effects as well as preparation method and application of compound
ActiveCN109438525AEnhanced inhibitory effectTreatment targetingOrganic active ingredientsPhotodynamic therapyPentamethylcyclopentadieneStructural formula
The invention discloses a compound with chemotherapy and phototherapy anti-tumor effects. The chemical name of the compound is monochloro-chloro-(9-anthracene-N4-methylthiosemicarbazide)-pentamethylcyclopentadienyl rhodium (III), and the structural formula of the compound is shown in the description. The compound has good inhibitory effects on human prostate cancer PC3 cells, human ovarian cancerSKOV3 cells, and high blood pressure, and can be used for preparing drugs for treating prostate cancer, ovarian cancer and hypertension.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Compound with anti-tumor effect as well as preparation method and application thereof
ActiveCN109232662AEnhanced inhibitory effectTreatment targetingRhodium organic compoundsAntineoplastic agentsPentamethylcyclopentadieneAnthracene
The invention discloses a compound with an anti-tumor effect. The chemical name of the compound is monochloride-chlorine-(9-anthracene-N<4>-phenyl thiosemicarbazide)-pentamethyl cyclopentadienyl rhodium (III); the structure formula of the compound is shown in description. The compound has a very good inhibition effect on human prostate cancer PC3 cells and human ovarian cancer SKOV3 cells, and canbe used for preparing medicine for treating prostate cancer and ovarian cancer.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Application of gweicurculactone in aspect of treating gynecological tumor
InactiveCN109481432AStrong growth inhibitory effectHydroxy compound active ingredientsAntineoplastic agentsGynecologic TumorIsorupestonic acid
The invention discloses application of gweicurculactone in the aspect of treating gynecological tumor. The application finds gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene have excellent proliferation inhibiting effect on human ovarian cancer SKOV3 cell and human cervical cancer Hela cell; although camelliene is a dehydration product of ledol in chemical structure which is similar, camelliene is different from ledol in activity of inhibiting proliferation of the human ovarian cancer SKOV3 cell and the human cervical cancer Hela cell, wherein camelliene has obvious inhibiting effect on human cervical cancer Hela cell proliferation and unobvious inhibiting effect on human ovarian cancer SKOV3 cell proliferation, but ledol has obvious inhibiting effect on human ovarian cancer SKOV3 cell proliferation and unobvious inhibiting effect on human cervical cancer Hela cell proliferation. Camelliene, ledol, gweicurculactone, isorupestonic acid, 7-aromadendrene-6-ketone and 4-aromadendrene can all be used for treating the gynecological tumor.
Owner:淮安培元基因科技有限公司
Application of ovarian cancer cells in preparation of medicine for treating pancreatic cancer
InactiveCN114010657ASignificant effectPharmaceutical delivery mechanismMammal material medical ingredientsSubcutaneous injectionPharmaceutical drug
The invention discloses an application of ovarian cancer cells in a medicine for treating pancreatic cancer, and belongs to the field of biological medicines. The ovarian cancer cells are obtained by culturing human ovarian cancer SKOV3 cells, the ovarian cancer cells and a pharmaceutically acceptable carrier are prepared into a medicine for treating and / or preventing pancreatic cancer, and administration treatment is carried out in a subcutaneous injection or surgical transplantation mode. Animal experiments prove that the ovarian cancer cells have great potential as drugs for treating pancreatic cancer, the good curative effect of the ovarian cancer cells on pancreatic cancer is disclosed for the first time, and an effective novel potential alternative therapy is provided for pancreatic cancer treatment.
Owner:北京箭牧科技有限公司
Application of a kind of timosaponin I in the preparation of anti-human ovarian cancer drug
ActiveCN113509479BPrevent proliferationInhibit migrationOrganic active ingredientsAntineoplastic agentsSignalling pathwaysPharmaceutical drug
The invention provides an application of timosaponin I in the preparation of an anti-human ovarian cancer drug, which belongs to the technical field of new medical applications of timosaponin I, wherein the molecular formula of timosaponin I is C 39 h 66 o 14 , the chemical structural formula is: timosaponin I of the present invention can effectively inhibit the expression of mRNA and protein GLI1 and SUFU of SHH signaling pathway-related target genes in human ovarian cancer cell SKOV3, and timosaponin I can effectively inhibit the expression of SKOV3 cells Proliferation, epithelial-mesenchymal transformation (Epithelial-mesenchymal transformation, EMT), migration and invasion, show that timosaponin I of the present invention is expected to be developed as an active ingredient of anti-human ovarian cancer drugs; According to the needs of patients, it can be made into different preparation forms, which is convenient for patients to take, and has good development and application prospects.
Owner:NANJING MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com